CYTOF Altamira Therapeutics Ltd. IFRS Annual reports only
Pharmaceutical Preparations · OTC · SEC CIK 1601936 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2024*2024-12-31 · USD | FY20232023-12-31 · CHF | FY20232023-12-24 · CHF | FY20222022-12-31 · CHF | FY20222022-12-24 · CHF |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | 379 | — | 305,616 | — |
| Cost of revenue | — | 33,967 | — | 1.44M | — |
| Gross profit | — | -33,588 | — | -1.14M | — |
| R&D expense | $3.73M | 3.04M | — | 14.62M | — |
| SG&A expense | $3.20M | 3.14M | — | 3.40M | — |
| Operating income | -$6.85M | -5.92M | — | -18.01M | — |
| Interest expense | $0 | 1.01M | — | 911,869 | — |
| Pretax income | -$8.46M | -7.27M | — | -18.66M | — |
| Income tax | — | — | — | -7,919 | — |
| Net income | -$8.46M | -3.87M | — | -26.53M | — |
| EPS (basic) | -2.99 | -7.88 | — | -582.58 | — |
| EPS (diluted) | -2.99 | -7.88 | — | -582.58 | — |
| Weighted avg. shares (diluted) | 451,555 | 41,803 | — | 910,723 | — |
| Balance sheet | |||||
| Cash & equivalents | $998,624 | 617,409 | — | 15,395 | — |
| Receivables | — | — | — | 6,525 | — |
| Inventory | — | — | — | 11,644 | — |
| Current assets | $1.54M | 1.22M | — | 1.77M | — |
| PP&E, netmay include right-of-use assets (IFRS) | $100,000 | 1 | — | 1 | — |
| Intangibles | $4.63M | 3.89M | — | 3.89M | — |
| Total assets | $8.65M | 7.69M | — | 6.30M | — |
| Current liabilities | $1.16M | 888,914 | — | 12.88M | — |
| Short-term debt | — | — | — | 5.87M | — |
| Total liabilities | $2.09M | 1.24M | — | 14.62M | — |
| Shareholders' equity | $6.57M | 6.46M | — | -8.31M | — |
| Shares outstanding | 4.66M | 1.48M | — | 59,003 | — |
| Cash flow statement | |||||
| Operating cash flow | -$6.11M | -$12.81MUSD | — | -$9.09MUSD | — |
| Capital expenditure | $103,087 | — | — | — | — |
| Free cash flow | -$6.22M | — | — | — | — |
| Investing cash flow | -$115,341 | 1.44M | — | -2.14M | — |
| Financing cash flow | $6.51M | 10.62M | — | 9.83M | — |
| Stock-based compensation | $532,081 | 379,414 | — | 342,799 | — |
Free plan shows the latest 5 periods; Pro shows all 13 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.